Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Maxamine scheduled for December advisory panel review

Sep. 20, 2000

Cel-Sci receives grant for cervical cancer study with Multikine

Sep. 20, 2000

Phase I/II clinical trial demonstrates safety and tolerability of GVAX lung cancer vaccine

Sep. 15, 2000

Novel duocarmycin derivative suitable for use in anticancer immunoconjugates

Sep. 15, 2000

NCI sponsors additional phase II studies of Prostvac VF vaccine

Sep. 13, 2000

StressGen commences phase II trial of HspE7 for treatment of cervical cancer

Sep. 12, 2000

Maxamine granted priority FDA review for melanoma

Sep. 8, 2000

Herceptin approved in E.U. for treatment of HER2-positive metastatic breast cancer

Aug. 30, 2000

Cancer vaccine shows potential for decreasing risk of relapse and death

Aug. 30, 2000

LifeTime Pharmaceuticals announces U.S. phase I/II trials of Beta LT for cancer

Aug. 29, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...